NEW YORK, April 30, 2020 /PRNewswire/ -- Spruce Point Capital Management has issued a letter sent to the management of Advent International ("Advent") recommending that Advent critically reexamine its agreement to purchase Forescout Technologies, Inc. ("Forescout" or "the Company"). Accompanying the letter is a report supporting our view that the deal price could be revised lower by up to 35%-50%, if not called off entirely. We will be sharing details of our thoughts and research opinions throughout the day exclusively on Twitter @sprucepointcap.
On February 6, 2020 Forescout announced its purchase by Advent for $33/share in a $1.8bn deal. We believe investors ascribe too high a probability that it's a done deal. Upon conducting a forensic analysis of deal proxy statements, we observe that some financial forecasts reviewed by Forescout internally may not have been shared with prospective acquirers – and that some of these forecasts were materially worse than those known to be disclosed to buyers. Whether or not this represents a breach of reps and warranties, we believe it should serve as grounds for Advent to negotiate a lower share price. Advent's interest in revisiting the terms should be high given that the deal was struck just weeks prior to the WHO declaring COVID-19 a pandemic, which we believe dramatically alters the financial outlook for Forescout, a negative EBITDA business which was already under growth pressures and missing its guidance. Importantly, with the onset of the pandemic, Spruce Point estimates that it is likely in Advent's interest to walk away from the deal – even after taking into account its $112M termination fee.
We believe Advent substantially overpaid, underscored by Investcorp's recent purchase of Avira in early April. Avira, a profitable cybersecurity company, was acquired at a revenue multiple >50% less than that of Forescout's. We believe that Advent can, and should, use this as leverage to renegotiate the deal price lower. In our opinion, Advent, a steward of public pension capital, must negotiate a lower deal price more reflective of Forescout's ominous outlook, rather than unjustly enriching management with a $100m payday, and early VCs for having created limited / no value as a public company in our opinion.
Spruce Point estimates that, given (1) Advent's potentially incomplete view into Forescout's financials during the negotiation process, and (2) pandemic-related developments which we believe erode the Company's outlook going forward, a conservative reevaluation of the deal featuring NO multiple compression could see Advent value FSCT more than 20% below the $33/share deal price. Despite facing a $112M termination fee, a straight-forward cost/benefit analysis reveals that, at the current terms, Advent would do better to walk away from the deal rather than complete it. We believe that, in a realistic scenario in which Forescout's projections are revised downward, and the multiple compressed, Forescout shares should be valued between $17-$22 regardless of whether the deal is renegotiated or annulled completely, yielding 35%-50% downside to the $33 price.
Spruce Point Capital has a short position in Forescout (NASDAQ: FSCT) and stands to benefit if its share price falls.
The research note can be found at www.sprucepointcap.com and updates will be posted on twitter @sprucepointcap.
See the other side of the Wall Street hype machine.